What happens to stocks if AI loses momentum?
Investing.com - Jefferies has reduced its price target on Inovio Pharmaceuticals (NASDAQ:INO) to $1.80 from $2.00 while maintaining a Buy rating on the stock. The company’s shares currently trade at $1.49, down over 80% in the past year, though InvestingPro analysis suggests the stock may be undervalued at current levels.
The firm notes that Inovio is focusing on advancing its ’3107 product for Recurrent Respiratory Papillomatosis (RRP), with the company expecting to begin a rolling submission in the second half of 2025 and anticipating Biologics License Application (BLA) acceptance by year-end 2025.
Jefferies indicates this timeline could support potential approval for the product by mid-2026, while also monitoring a key competitor’s PDUFA date in August 2025 for potential implications on Inovio’s prospects.
The research firm highlighted that Inovio’s ’3107 confirmatory trial uses a randomized controlled trial design, which differs from a competitor’s single-arm design that may face uncertainties amid recent changes in FDA leadership.
According to Jefferies, Inovio reported $47.5 million in cash and expects its financial runway to extend into the second quarter of 2026, bolstered by a $22.5 million capital raise completed in July 2025.
In other recent news, Inovio Pharmaceuticals reported a significant reduction in losses for the second quarter of 2025. The company managed to decrease its operating expenses by 31%, and the net loss per share was nearly halved. These financial results met both JMP Securities’ and consensus estimates. JMP Securities has reiterated its Market Outperform rating for Inovio, maintaining a price target of $12.00. The firm highlighted that Inovio is on track to complete its Biologics License Application by the end of 2025. Current funding is expected to sustain the company’s operations into the second quarter of 2026. These developments indicate progress in Inovio’s financial and operational strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.